welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional Performance
study id #: NCT03534349
condition: Duchenne Muscular Dystrophy, Performance, Flexibility
The investigator investigated the effect of lower limb flexibility on functional performance of children with Duchenne Muscular Dystrophy.
mechanism of action: No pharmaceutical intervention
last updated: November 21, 2018
start date: January 2017
estimated completion: June 2017
size / enrollment: 30
Thirty children whose functional levels were in 1 or 2 according to the Brooke Lower Extremity Functional Classification Scale were included in the study. Flexibilities of hamstrings, hip flexors, tensor fascia latae, and gastrocnemius muscles were evaluated in dominant lower limb. Popliteal angle test, hip flexor flexibility test, tensor fascia latae flexibility test and gastrocnemius flexibility test were used for flexibility asssessments. Functional performance was assessed with 6 Minute Walk Test (6 MWT) and Timed Performance Tests. The correlation between the flexibility of lower limb muscles' and performance tests were examined.
- 6 Minute Walk Test [ Time Frame: 6 Minute ]
The 6 Minute Walk Test (6MWT) is a standard test recently used to evaluate functional capacity in neuromuscular diseases, and found to be a safe and valid test that can be performed in Duchenne Muscular Dystrophy
- Timed Performance Test [ Time Frame: 3 minute ]
Timed performance tests such as 10 m walk, Gower's (from supine position to stand up), ascending/descending 4 steps were also performed. During these tests, the child's performance was recorded in seconds.
• Having a Duchenne Muscular Dystrophy diagnosis,
• Being in the ambulatory period and climbing four steps independently,
• To be able to cooperate the physiotherapist's directions,
• Not having any severe contracture in the lower limbs which may prevent assessments,
• Not having any injury or surgery involving the lower limbs during the last 6 months.
Children who did not provide these criteria and did not will to participate the study were excluded.
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of the study is to see wheth...
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
Study of DS-5141b in Patients With Duchenne Muscular DystrophyThis is a phase I/II study to evaluate t...
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...